By Alan Wolf, YSN
Serta Simmons Bedding has partnered with Swiss textile chemistry firm HeiQ to create a mattress that can reportedly kill the COVID-19 virus.
The new product, which awaits approvals from the U.S. Food & Drug Administration (FDA) and the Environmental Protection Agency (EPA), incorporates HeiQ’s patented Viroblock technology. Applied to fabric, Viroblock’s microsilver and vesicle components can attract, envelop, break down and ultimately kill virus particles and bacteria, Serta said, and studies show a 99.99 percent effectiveness against Sars-Cov-2, the virus that causes COVID-19.
Serta noted that coronavirus can pass through sheets and live on traditional mattresses, where it can remain infectious for days.
Tests indicate that fabrics infused with Viroblock can retain their antiviral properties for three years and their antibacterial qualities for two decades, the bedding maker said. The company plans to apply the process to all hospitality bedding and portions of its retail portfolio, including the Serta, Beautyrest and Tuft & Needle brands. It has also prepared an extensive media campaign to promote the proprietary technology that begins this week and extends into the fall.
“We know that our partners in the hospitality and healthcare industries are doing everything they can to help provide the cleanest environment and reassure their guests,” said David Swift, Chairman and CEO of Serta Simmons Bedding. “Antiviral and antibacterial mattresses will be an enormous asset in that effort.”
No date has been set for a U.S. launch, which is pending confirmation of Viroblock’s antiviral claims by the federal agencies. The technology has already been approved in Europe for use in medical personal protective equipment, Serta said.